Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450859 · ClinicalTrials.gov registry record · Phase 2
A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by BicycleTx Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT07450859: Recruiting Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by BicycleTx Limited.
NCT07450859 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC) that is actively recruiting participants, run by BicycleTx Limited. The registered enrollment target is 39 participants, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07450859, a Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), is actively recruiting participants, sponsored by BicycleTx Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 study for BT5528 in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, BT5528, is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive BT5528, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.
Primary Outcome
Percentage of participants who achieve a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator
Conditions Studied
Interventions
- DRUG BT5528
Study Locations (1)
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2026-03 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
What NCT07450859 shows while recruiting
NCT07450859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (PDAC) appearing as the primary indexed condition, and to 1 intervention - of which BT5528 is the first listed.
NCT07450859 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07450859 about?
NCT07450859 is a clinical study titled "A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)". This is a Phase 2 study for BT5528 in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, BT5528, is designed to find a specific protein called EphA2. The main aims of the st...
What is the current status of trial NCT07450859?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2026-03. Estimated completion is 2029-05.
What conditions does trial NCT07450859 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (PDAC).
What interventions are being tested in trial NCT07450859?
The interventions under investigation include: BT5528 (DRUG).
Who is sponsoring clinical trial NCT07450859?
This trial is sponsored by BicycleTx Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07450859 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma (PDAC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07450859's enrollment target sits among peer trials
39 14th of 16 higher than 3 of 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma (PDAC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
EUS-RFA PANCARDINAL-1 Trial
RECRUITING · Phase 2
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia